Noticias y Actividades de Regeneron Pharmaceuticals
Presencia
Regeneron Pharmaceuticals es una de las ...
- Forbes Global 2000 (#427);
- Fortune 500 (#311);
- Nasdaq 100;
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Regeneron Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización REGN (US).
Ellos se encuentran en:
- Farmacia50%
- Biotecnología50%
Ejecutivos
Ver el organigrama con sus 101 ejecutivos principales
Biografías más buscadas en Regeneron Pharmaceuticals
- Leonard Schleifer, President, Chief Executive Officer, Director
- Bonnie Bassler, Chairman of the Board
- Huda Zoghbi, Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Regeneron Pharmaceuticals.
Farmacia
Regeneron Pharmaceuticals tiene 1.830 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).
Popular M&A news in Farmacia
- Chimerix and Chimerix have merged (publicado el 22 de abril de 2025)..
- Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
- Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Regeneron Pharmaceuticals
- CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis | Regeneron Pharmaceuticals Inc.
- https://newsroom.regeneron.com/node/24391/pdf
- https://newsroom.regeneron.com/node/24386/pdf
- Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus) | Regeneron Pharmaceuticals Inc.
- Dupixent® (dupilumab) Significantly Reduced Severe Asthma Attacks in Children and is the Only Biologic to Demonstrate Improvement in Children's Lung Function in a Randomized Phase 3 Trial | Regeneron Pharmaceuticals Inc.
- Regeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020 | Regeneron Pharmaceuticals Inc.
- Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients | Regeneron Pharmaceuticals Inc.
- Late-breaking ESMO Presentation Shows Libtayo® (cemiplimab) Monotherapy Increases Overall Survival in First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50% | Regeneron Pharmaceuticals Inc.
- Press Releases | Regeneron Pharmaceuticals Inc.
- Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO | Regeneron Pharmaceuticals Inc.
- View more press releases Close
Redes sociales sobre Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Regeneron Pharmaceuticals en LinkedIn, Twitter y YouTube
